Pyxis Oncology (NASDAQ:PYXS) Trading Up 3.6% - What's Next?

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) shares traded up 3.6% during mid-day trading on Monday . The company traded as high as $1.16 and last traded at $1.14. 617,104 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 734,339 shares. The stock had previously closed at $1.10.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Monday, May 19th. Royal Bank Of Canada reissued an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Pyxis Oncology presently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Trading Down 2.5%

The stock has a 50 day simple moving average of $1.19 and a 200 day simple moving average of $1.24. The stock has a market cap of $71.86 million, a P/E ratio of -0.73 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Equities analysts anticipate that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC lifted its holdings in Pyxis Oncology by 53.8% during the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock worth $4,650,000 after buying an additional 1,043,228 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Pyxis Oncology by 57.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock worth $939,000 after buying an additional 219,100 shares during the period. 683 Capital Management LLC lifted its holdings in Pyxis Oncology by 32.5% during the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock worth $539,000 after buying an additional 135,000 shares during the period. Pier 88 Investment Partners LLC lifted its holdings in Pyxis Oncology by 296.6% during the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after buying an additional 292,370 shares during the period. Finally, Ridgeback Capital Investments L.P. acquired a new position in Pyxis Oncology during the 4th quarter worth about $560,000. Institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.